CA2546945A1 - Fiber optic device for sensing analytes - Google Patents

Fiber optic device for sensing analytes Download PDF

Info

Publication number
CA2546945A1
CA2546945A1 CA002546945A CA2546945A CA2546945A1 CA 2546945 A1 CA2546945 A1 CA 2546945A1 CA 002546945 A CA002546945 A CA 002546945A CA 2546945 A CA2546945 A CA 2546945A CA 2546945 A1 CA2546945 A1 CA 2546945A1
Authority
CA
Canada
Prior art keywords
optical
attached
tip
sensing element
distal end
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002546945A
Other languages
French (fr)
Other versions
CA2546945C (en
Inventor
Javier Alarcon
Kristin Weidemaier
Terry J. Amiss
John D. Denuzzio
Christopher C. Herdman
Ross Wayne Jacobson
J. Bruce Pitner
Douglas B. Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Becton, Dickinson And Company
Javier Alarcon
Kristin Weidemaier
Terry J. Amiss
John D. Denuzzio
Christopher C. Herdman
Ross Wayne Jacobson
J. Bruce Pitner
Douglas B. Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becton, Dickinson And Company, Javier Alarcon, Kristin Weidemaier, Terry J. Amiss, John D. Denuzzio, Christopher C. Herdman, Ross Wayne Jacobson, J. Bruce Pitner, Douglas B. Sherman filed Critical Becton, Dickinson And Company
Publication of CA2546945A1 publication Critical patent/CA2546945A1/en
Application granted granted Critical
Publication of CA2546945C publication Critical patent/CA2546945C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/77Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
    • G01N21/7703Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator using reagent-clad optical fibres or optical waveguides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings

Abstract

A device for sensing analyte concentration, and in particular glucose concentration, in vivo or in vitro is disclosed. An optical conduit, preferably an optical fiber has an optical system at the proximal end of the optical conduit. A sensing element is attached to the distal end of the optical conduit, and comprises at least one binding protein adapted to bind with at least one target analyte. The sensing element further comprises at least one reporter group that undergoes a luminescence change with changing analyte concentrations. Optionally, the sensing element includes reference groups with luminescence properties that are substantially unchanged by variations in the analyte concentrations.

Description

Fiber Optic Device for Sensing Analytes FIELD OF THE INVENTION
[0001] The present invention relates to a device that can be used to monitor concentrations of physiologically relevant compounds.
BACKGROUND OF THE INVENTION
[0002] Monitoring ira vivo concentrations of physiologically relevant compounds to improve diagnosis and treatment of various diseases and disorders is a desirable goal and would eWance the lives of many individuals. Advances in this area show particular promise in the area of facilitating adequate metabolic control in diabetics. CmTently, most diabetics use the "finger stick" method t0 1110111101' blood glucose level, and patient compliance is problematic due to pain caused by frequent finger sticks. As a consequence, there have been efforts to develop non-invasive or minimally invasive in vivo and more efficient in vitro methods for frequent and/or continuous monitoring of glucose in the blood or other biological 2 0 fluids.
[0003] The approaches to frequent and/or continuous ir7 oioo monitoring tend to fall into two general categories: "non-invasive'' and ''minimally invasive." Non-invasive monitoring determines analyte levels by directly tracking spectroscopic changes in skin and tissue.
Infrared radiation and radio wave impedance spectroscopy are examples of this technology.
'5 Progress with these approaches has been slow due to the requirement for frequent calibration, reproducible sample illumination, and variances in spectroscopic backgrounds between individuals. The "minimally invasive" approach avoids direct extraction of blood from the body and relies on the monitoring of signal changes in biological fluids using an intermediate sensing element. Biosensors of this type are devices capable of providing specific quantitative or semi-quantitative analytical information using a biological recognition element that is combined with a transducing (detecting) element.
[0004] Most conventional systems for frequent or continuous analyte monitoring involve amperometric biosensors that employ enz5nnes such as glucose oxidase (GOx) to oxidize glucose to glucuronic acid and hydrogen peroxide, generating an electrochemical signal.
These sensors are subject to inaccurate measurement due to oxygen deficiency and buildup of oxidation by-products. An accurate measurement of glucose concentrations requires an excess of oxygen, which is generally not present in human blood or interstitial fluid. Also, the electrochemical reaction itself generates a buildup of oxidation byproducts that may inhibit and degrade both the enzyme and its protective layer.
[0005] Biosensors based on optical rather than electrochemical sig~ials have also been developed and may offer significant improvements in stability and calibration.
For example, referencing an analyte-dependent optical signal against a second analyte-independent signal can courect for sources of noise and instability in the sensor. However, the potential of optical sensing for in nivo analyte detection has not yet been realized. One reason for this is that many current optical sensing methods rely on enzymatic chemistry such as glucose 2 0 oxidase. I11 Olle CO111111011 method, an oxygen-sensitive fluorescent dye is used to monitor the consumption of oxygen by the GOx enz5nnatic reaction. Although this is an optical biosensor, with the fluorescence signal level varying with changing oxygen levels, such a sensor is subject to the same problems as amperometric devices based on this same chemistry: oxygen deficiency and enzyme degradation.
~' 5 [0006] To overcome the challenges associated with enzyme sensing (e.g., GOx), whether electrochemical or optical, non-enzymatic protein-based optical or fluorescent sensing is being explored. Labeled concanavalin A and dextran have been used to create a competitive FRET assay; however, this system requires entrapment of both components, and the dynamic range of the assay is limited. See Ballerstadt, R., Schultz, J.S.;
''Competitive-binding assay method based on fluorescence quenching of ligands held in close proximity by a multivalent receptor." Anal. Chem. Acta 345 (1-3): 203-212 (1997). See also, Russell, R.J., Pishlco M.V., Gefrides C.C., McShane, M.J., Cote, G.L.; "A fluorescence-based glucose biosensor using concanavalin A and dextran encapsulated in a polyethylene glycol) hydrogel"
Anal. Chem.
71 (15): 3126-3132 (1999).
[0007] Another protein-based sensing chemistry uses the Eschericl7ia coli (E.
coli) periplasmic receptor, glucose-galactose L~inding protein (GGBP) to generate a fluorescence signal in response to glucose binding. See, for example, Tolosa, L., I.
Gryczynski, L. R.
EiclW om, J. D. Dattelbaum, F. N. Castellano, G. Rao, and J. R. Lakowicz;
''Glucose sensor for low-cost lifetime-based sensing using a genetically engineered protein"
Anal. Biochem.
267:114-120 (1999); Hellinga, H. W., and J. S. Marvin; ''Protein engineering and the development of generic biosensors. Trends Bioteclmlol" 16:183-189 (1995);
Salins, L. L., R.
A. Ware, C. M. Ensor, and S. Dauneu; "A novel reagentless sensing system for measuring glucose based on the galactose/glucose-binding protein" Anal Biochem 294:19-26 (2001);
and de Lorimier, R. M., J. J. Smith, M. A. Dwyer, L. L. Looger, IC. M. Sali, C. D. Paavola, S.
S. Rizl:, S. Sadigov, D. W. Conrad, L. Loew, and H. W. Hellinga. "Construction of a 2 0 fluorescent biosensor family" Protein Sci. 11:2655-2675 (2002). GGBP
undergoes a substantial conformation change upon ligand binding, trapping the ligand between its two globular domains. See, for example, Shilton, B. H., M. M. Flocco, M. Nilsson, and S. L.
Mowbray; "Conformational changes of tlwee periplasmic receptors for bacterial chemotaxis and transport: the maltose-, glucose/galactose- and ribose-binding proteins"
J. Mol. Biol.
5 264:350-363 (1996). By site-specifically labeling the protein with an enviromnentally sensitive fluorophore this attribute can be exploited to generate a fluorescent signal. See, for example, Salins, L. L., R. A. Ware, C. M. Ensor, and S. Daunel~t; "A novel reagentless sensing system for measuring glucose based on the galactose/glucose-binding protein" Anal Biochem 294:19-26 (2001). Because GGBP neither consumes glucose nor generates reaction products, it can be used as a reagentless sensor. This may provide greater accuracy and reliability than amperometric biosensors.
[0008] While a numt~er of groups have developed GGBP mutations capable of responding to glucose in the physiological range, there have been no reports of a functional biosensor device based on binding protein technology that is suitable for irT
vivo analyte monitoring. A functional frequent and/or continuous biosensor must couple the sensing element to the optical sensing elements while maintaiung sensor integrity and functionality as well as patient comfort. For example, the biological recognition element and accompanying transducing element should preferably be incorporated within biocompatible material that shields the sensing element from the immune system, permits analyte diffusion in and out, and avoids leaching Ot the SellSlllg elelllellt into the patient blood or other biological fluid (e.g., interstitial fluid). Since binding proteins require orientational control and confounational freedom to enable effective use, many physical absorption and random or bulk covalent surface attaclunent or immobilization strategies as taught in the literature generally are either suboptimal or unsuccessful. Fuuther, a means for inteurogating the sample with light in a reproducible and/or controlled fashion must be devised.
2 0 (0009] Cane approach generally known is to couple the sensing element to one end of an optical fiber and to couple the optical elements such as excitation sources or detectors to the other end. However, coupling of binding proteins to one end of an optical fiber is subject to the above-mentioned challenge of preserving confounational and/or onientational mobility of the protein. In addition, fiber optic cabling is often impractical from a patient-use point of 2 5 view since patients may need to remove or replace the sensor periodically.
Replacement of the entire fiber can be costly and inconvenient. Finally, the optical system, comprising, e.g., excitation sources, detectors, and other optical elements must be sufficiently robust to tolerate or correct for changes in optical aligrnnent due, for example, to patient motion or drift of the electronics in the optical reader. The optical system must also be sufficiently sensitive to detect signal from reporter dyes without relying on high power consumption and/or large-sized elements that would render the system unpontable and hence unwearable.
[0010] Accordingly, there is a need for a biosensor that incorporates in its sensing element a binding protein with conformational and/or orientational mobility coupled to optical sensing elements that provide a wearable and robust device.
SUMMARY OF THE INVENTION
[0011] An object of the present invention is to provide a device for sensing the concentration of a target analyte in a sample. The sample may be blood, saliva, tears, sweat, urine, cerebral spinal fluid, lymph fluid, interstitial fluid, plasma, serum, animal tissue and media. The device comprises: (i) an optical conduit having a proximal end and a distal end;
(ii) an optical system at the proximal end of the optical conduit that contains at least one electromaD ietic energy emitter and at least one electromagnetic energy detector; and (iii) a sensing element in optical proximity to the distal end of the optical conduit that comprises at least one binding protein that is adapted to bind with at least one target analyte; said sensing element also comprising at least one repouter group, and optionally one or more reference 2 0 groups.
[0012] The optical conduit, which may vary in length fiom approximately 0.1 cm to 1 meter, couples light into and out of the optical system and into and out of the sensing element. For example, the optical conduit may be a lens, a reflective charnel, a needle, or an optical fiber. The optical fiber may be either a single strand of optical fiber (single or 2 5 multimode) or a bundle of more than one fiber. In one embodiment, the bundle of fibers is bifurcated. The fiber may be non-tapered or tapered so that it can penetrate the skin of a patient.
(0013] The optical system consists of a combination of one or more excitation sources and one or more detectors. It may also consist of filters, diclu-oic elements, a power supply, and electronics for signal detection and modulation. The optical system may optionally include a microprocessor.
[0014] The optical system intewogates the sample either continuously or intermittently by coupling one or more interrogating wavelengths of light into the optical conduit. The one or more interrogating wavelengths then pass through the optical conduit and illuminate the sensing element. A change in analyte concentration results in a change of the wavelength, intensity, lifetime, energy transfer efficiency, and/or polarization of the luminescence of the repouter group, which is a part of the sensing element. The resulting changed luminescence sigmal passes back tlm~ough the optical conduit to the optical system where it is detected, interpreted, and stored and/or displayed. In certain embodiments, the optical system comprises multiple excitation sources. One or more of these sources may be modulated to permit dynamic signal processing of the detected signal, thereby eWancing signal-to-noise and detection sensitivity. Modulation may also be used to reduce power consumption by the device or to increase the lifetime of the sensing element by minimizing undesirable phenomena such as photobleaching. The optical system can also include one or more 2 0 electromagnetic energy detectors that can be used for detecting the luminescence signal fiom the reporter and optional reference groups as well as for internal referencing and/or calibration. The overall power consumption of the optical system is kept small to pernit the device to be operated using battery power.
[0015] The sensing element comprises one or more binding proteins that are adapted to 2 5 bind with at least one target analyte, and at least one reporter group. A
suitable binding protein may be any that is adapted for use as a biosensor. For example, the suitable binding protein may be any one of those described in copending, commonly owned U.S.
Patent Application Serial No. 10/039,833 filed January 4, 2002; U.S. Patent Application Serial No.
10/040,077 filed January 4, 2002; U.S. Patent Application Serial No.
10/039,799 filed January 4, 2002; and U.S. Patent Application for ''C0111pOS1t1011S alld MethOClS for Measuring Analyte Concentrations" to Tehl~y Amiss, et al. (attorney docket no. P-6011 ) filed on even date herewith, the contents of which are incorporated herein by reference in their entirety.
Suitable binding proteins may also be any one of those described in U.S.
Patent No.
6,277,627, U.S. Patent No. 6197534, or WO 03/060464 A2 the entire contents of which are incorporated herein by reference in their entirety.
[0016] The reporter group, which is associated with the binding protein, is adapted to undergo a luminescence change upon binding of the binding protein to the target analyte. As used herein, the term ''associated with" means that the repol-ter group is covalently or non-covalently associated with the binding protein such that upon blndmg of a target analyte to the L~inding protein, there is a change in the reporter group's luminescence properties such as wavelength, intensity, lifetime, energy transfer efficiency, and/or polarization. Examples of reporter groups include, but are not limited to, organic dyes, pairs of organic dyes, fluorescent or bioluminescent fusion proteins, pairs of fluorescent or bioluminescent fusion proteins, or any combination of the above. The reporter group may consist of a donor and acceptor undergoing fluorescence resonance energy transfer. Other luminescent labeling moieties 2 0 include lanthanides such as europium (Eu3+) and terbium (Tb3+), as «lell as metal-ligand complexes, including those of ruthenium [Ru (II)], rhenium [Re(I)], or osmium [Os (II)] , typically in complexes with diimine ligands such as phenantln-olines.
[001?] The sensing element is in optical proximity to the optical conduit.
"Optical proximity'' means that components of the device are close enough to one another such that an 2 5 optical signal can be transmitted to or received from one object by another. The sensing element may be placed in optical proximity to the optical conduit in a number of ways, for example: attached directly to the optical conduit; attached to a connector that is attached to the optical conduit; attached to a polymer chain or a polymer matuix that is attached to the optical conduit; or attached to a polymer chain or a polymer matrix that is attached to a connector that is attached to the optical conduit. The sensing element may be peunanently affixed to the optical conduit or replaceably attached such that the sensing element can be replaced conveniently and economically.
[0018] In another embodiment, the sensing element may further comprise one or more reference groups. Unlike the reporter group, the reference group has a luminescence signal that is substantially unchanged upon binding of the target analyte to the binding protein.
"Substantially unchanged" means the luminescence change of the reference group is significantly less than the luminescence change undergone by the repouter gn~oup. The reference group, which can consist of luminescent dyes and/or proteins, is used for internal referencing alld calibration. The reference group can be attached to any number of components of the device including the sensing element, a binding protein not containing the repouter group, the polymer matrix, the polymer chain, a biomolecule that is not a binding protein, the optical conduit, or a tip.
[0019] The sensing element (typically this refers to the binding protein with the associated reporter group and optional reference group) may be attached directly to the distal end of the optical conduit using for example covalent, ionic, or van der Waals interactions, ? 0 dip coating, spin coating, plasma coating, or vacuum deposition. The sensing element may also be attached to a connector, which allows the sensing element to be readily detachable so that it becomes replaceable.
[0020] In another embodiment, the sensing element is attached to or inunobilized in a polymeric matrix. The polymer matrix may be any matrix that permits free diffusion of the 5 analyte of interest into and out of the matrix, while excluding interfering immune proteins and proteases and allows the binding protein to retain some degree of conformational and/or orientational mobility. The matrix may consist of multiple layers, with an imier layer seining to retain the binding protein, and one or more outer layers to control the permeability and/or achieve biocompatibility. For example, the pol5nner matrix may be any one of those described in copending, CO1Tll110111y owned U.S. Application Serial No.
10/428,295, filed May 2, 2003, the entire contents of which are incorporated herein by reference.
The immobilization may be accomplished either by covalently linking the sensing element to the polymer matrix or by physically entrapping the sensing element within the matrix. In the instance where the polymer matuix physically entraps the sensing element, the matrix pores are sized to retain the sensing element. In the embodiment where the sensing element is attached to the polymeric matrix, the sensing element is attached to the matrix using, for example, covalent or ionic liucage. The polymer matrix can be attached to the distal end of the optical conduit using adhesives, dip or spin coating, plasma coating, covalent, ionic, or van der Waals interactions, a mechanical connector or combinations thereof.
[0021] In another embodiment, the sensing element is attached to a polymeric chain. The method of attaching the sensing element to the polymeric chain includes, but is not limited to, covalent, ionic, and van der Waals interactions and combinations thereof. The polymer chain is attached to the distal end of the optical conduit using, for example, dip or spin coating, plasma coating, vacuum deposition, covalent, ionic, or van der Waals interactions, or combinations thereof.
[0022] In another embodiment, the device further comprises a tip (either tapered or non-tapered) that is designed to pierce the skin to allow the sensing element to contact body fluids. Preferably, the tip is disposable. The tip may be made of plastic, steel, glass, pol5nner, or any combination of these or similar materials. The tip may be attached directly to the optical conduit (fiber) using adhesives or a mechanical fitting. The tip may also be used to 5 house the optical conduit containing the sensing element, such that it encases the optical conduit and sensing element. W one embodiment, the sensing element may be contained within the tip.
[0023] The device may further comprise a connector that may be used to attach the components of the device to one another. The connector may be, for example, any mechanical device, such as standard fiber optic comiectors, luer locks, plastic, metal, or glass sleeves, or spring-loaded housings. For instance, the comiector may be used to attach the sensing element to the optical conduit, or to attach the optical conduit to the optical system.
The primary purpose of the connector is to provide a component that allows the other components to be readily detachable so that the component becomes replaceable.
[0024] In light of the foregoing connnents, it will be recognized that a principal object of the present invention is to provide an improved device for sensing the concentration of a target analyte that is wearable and easy to operate. Preferably, the device may be used for continuous analyte monitoring, but someone skilled in the art could envision continuous and episodic monitoring of isn voo and/or in nits°o samples with such a device.
[0025] Another object of the present invention is to provide a device that is compact in design and portable.
[0026] A further object of the present invention is to provide a device for sensing a target analyte that is robust.
[0027] A further object of the present invention is to provide a device that can be easily 2 0 employed with highly reliable results.
[0028] Another object of the present invention is to provide a device that is accurate and provides readings in a short time span.
[0029] Another object of the present invention is to provide a device that has a tip portion of a size so that it produces little or no pain or sensation when inserted into a patient.
to [0030] These and other objects and advantages of the present invention will become apparent after considering the following detailed specification in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The invention will be more readily understood with reference to the embodiments thereof illustrated in the attached drawing figures, in which:
[0032] Figure 1 is a generalized schematic of a biosensor according to an embodiment of the invention;
[0033] Figure 2 illustrates two embodiments of the optical configuration in the optical portion of the sensor according to an embodiment of the present invention;
[0034] Figure 3 illustrates various embodiments of the biosensor tip according to an embodiment of the invention;
[0035] Figure 4 illustrates an embodiment of the invention that is a wearable in-vivo optical biosensor;
[0036] Figure 5 is a chant showing the performance of a fiber optic biosensor according to an embodiment of the invention tracking changing glucose levels in an anesthetized pig;
[0037] Figure 6 is a chart showing the performance of a fiber optic biosensor according to an embodiment of the invention using a single 400 micron core fiber optic sensor and the optical configuration illustrated in Figure 2A;
0 [0038] Figure 7 shows the performance of a fiber optic biosensor according to an embodiment of the invention using a single 400 micron core fiber optic sensor and the optical configuration illustrated in Figure 2A; and [0039] Figure S illustrates an embodiment of the present invention including multiple electromagnetic energy detectors and an internal reference.

[0040] Tluoughout the drawing figures, it should be understood that like numerals refer to like features and structures.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0041] The preferred embodiments of the invention will now be described with reference to the attached drawing figures. The following detailed description of the invention is not intended to be illustrative of all embodiments. lil describing prefeiTed embodiments of the present invention, specific terminology is employed for the sake of clarity.
However, the invention is not intended to be limited to the specific terminology so selected. It is to be uyderstood that each specific element includes all technical equivalents that operate in a similar mariner to accomplish a similar purpose.
[0042] The present invention involves a binding-protein engineered to bind an analyte of interest within a desired clinical or analytical range. In addition, one or more huminescent reporter groups are associated with the binding protein. These luminescent reporter guoups include but are not limited to, for example, organic aromatic dye molecules covalently coupled to cysteine residues in the protein or, for example, luminescent biomolecules such as proteins fused to the engineered binding protein. Cysteine or other amino acid groups may be engineered into the binding protein to provide sites of attaclunent for the luminescent reporter molecule. Binding of the analyte to the binding protein results in a change in the luminescent 0 properties of one or more reporter groups. The luminescent properly affected may be the absorption or emission wavelength, absorption or emission intensity, emission lifetime, emission polarization, and/or energy transfer efficiency. Binding of the analyte is also reversible, with the unbinding resulting again in a change in the luminescent properties of the repouter molecule.
? 5 [0043] The one or more binding proteins along with their associated reporter groups comprise the sensing element. Optionally, the sensing element may also contain one or more reference groups. Unlike the reporter group, the reference group has a luminescence signal that is substantially unchanged upon binding of the target analyte to the binding protein. The luminescence signal from the reference group provides an internal optical standard that can be used to correct for optical al-tifacts due to for example electronic drift in the optical system or to motion of the saW ple or optical conduit. The reference group can also tie used for calibration. The reference group can be attached to any number of components of the device including the sensing element, a L~inding protein not containing the reporter group, the polymer matrix, the polymer chain, a biomolecule that is not a binding protein, the optical conduit, or the tip. In one embodiment, the reference group is attached to a binding protein that has been engineered to show no significant response to the analyte at physiologically relevant concentrations.
[0044] The sensing element, compl-ising one or more binding proteins, one or more reporter groups, and optional reference groups, may be ilnlnobilized at the end of the optical conduit or inside a disposable tip that interfaces with the optical conduit.
Immobilization of the sensing element on the optical conduit or inside the disposable tip may be accomplished by depositing a thin layer of the sensing element, for example, by dip or spin coating, covalent attaclunent, plasma treatment, and the like directly onto the optical conduit or tip.
Alternately, the sensing element can be first immobilized in a polymeric matrix and the matrix then attached to the optical conduit, or tip either by adhesives, 111~eCtloll 11101d111g, dip 2 0 or spin coating, plasma coating, vacuum deposition, ink jet teclu~ology, covalent, ionic, or van der Waals interactions, by mechanical attachment or any combination thereof.
[0045] The optical system is capable of interrogating the luminescent response of the reporter and reference groups by passing light fi~om an electromagnetic excitation source down the optical conduit to the distal end containing the sensing element. The optical system 5 also monitors and interprets the retulTl signals generated by the luminescence response of the repol-ter group and reference group. The luminescent properties of the reporter group, either wavelength, intensity, lifetime, energy transfer efficiency, or polarization, change in response to analyte binding or unbinding from the binding protein.
(0046] Nov~ with reference to Figure 1 a specific exemplary embodiment of the present invention will be described. The optical system 2 includes a combination of elements including but not limited to electromagnetic energy emitters, electromagnetic energy detectors, various miiTOrs, filters, electronics, holographic optics, diclu-oic elements, and optical standards needed to send inteiTOgating radiation from the electromagnetic energy emitter down the optical conduit to the sensing element and then to resolve and inteyret the return luminescent signal. The return luminescent signal from the reporter group changes in response to changing concentrations of the analyte to be detected. The optical system 2 may also comprise a computer or microprocessor 3 which handles signal processing, mathematical manipulation of one or more signals, and data storage and handling. The computer or microprocessor 3 may be in physical contact with the other components of the optical system or, in a prefeiTed embodiment, may be physically separated by up to several meters fr0111 the other components of the optical system. In this embodiment, infounation from the electromagnetic energy detectors and electronic processing elements in the optical system is communicated wirelessly to the computer or microprocessor 3. The computer or microprocessor 3 may also store calibration infounation specific to the sensing element.
Light of one or more wavelengths produced in the optical system 2 is chamleled down an 2 0 optical conduit 4 to the sensing element 6. Optical conduit 4 may be either an optical fiber or a shout light guide that transmits light with minimal loss. The sensing element 6 consists of one or more binding proteins with one or more associated luminescent reporter groups either inunobilized in a polymeric matrix, attached to a pol5nner chain, incorporated in a disposable tip, attached directly to the distal end of the optical conduit, or attached to a comiector. The ~ 5 sensing element 6 can also consist of additional luminescent reference groups that are optionally attached to biomolecules, polymers, or organic molecules for the propose of providing a reference or calibration signal. Sensing element 6 can be attached to the distal end of optical conduit 4, either directly or via a pohnner matrix, or, in the prefeiTed embodiment, attached to a disposable tip 5 that is attached to the distal end of the optical conduit 4. W this case, the disposable tip 5 is positioned against optical conduit 4 either mechanically, via adhesive, or by any other suitable means known to those of skill in the art.
[0047] Figure 2 is an enlargement of the optical system 2 in two typical embodiments. In Figure 2A, a dichroic mirror or beamsplitter 11 is used to direct light from an electromagnetic energy source 7 to the optical conduit 4. Excitation sources may consist of, but are not limited to, for example arc lamps, laser diodes, or LEDs. In this embodiment, the optical conduit 4 is a fiber optic cable, and the same fiber is used to transmit excitation light from electromagnetic energy source 7 to the sensing element 6 and also to transmit the luminescence signals from the reporter or reference groups back to the optical system 2. A
diclwoic element 11 preferably separates the return signal from the excitation light and directs the signal to electromagnetic energy detectors 8. Detectors may consist of, but are not limited to, for example, photodiodes, CCD chips, or photomultiplier tubes. W
the event that multiple luminescent signals are returned from the sensing element, additional diclwoic elements may be used to direct portions of the return signals to multiple detectors.
Preferably, a luminescent reference group that is analyte insensitive is included along with the analyte-dependent reporter molecule to provide a reference signal. This reference signal can be used, for example, to correct for optical or electronic drift.
[0048] Figure 2B illustrates a second embodiment in which a bifurcated optical bundle or fused optical fiber awangement is used to transmit light to and from the sensing element.
Here, light from excitation source 7 is transmitted down one ann of the bifurcated fiber bundle. Return luminescent signals from the sensing element are detected using the second 5 ann of the bifurcated fiber, so that in this case the fiber bundling seines to separate excitation from return luminescence. Dicluoic optics, beamsplitters, or polarizers may additionally be 1, used to further divide the return luminescence, based for example on wavelength or polarization. Optionally, bandpass filters 1? can be used to select the luminescent wavelength to be detected. Power supply 9 supplies power to the optical system 2.
[0049] Figure 3 illustrates representative methods of attaching the sensing element to the end of an optical conduit, when the optical conduit is an optical fiber. In Figure 3A, the sensing element attached directly to the distal end of the optical fiber using for example covalent, ionic, or van der Waals interactions, dip coating, spin coating, plasma coating, vacuum deposition, ink jet teclmology, or combinations thereof. Alternately, the sensing element, comprising the binding proteins, associated repouter groups, and optional reference groups, can be attached to a long chain polymer, and the long chain polymer attached directly to the distal end of the optical fiber using for example, dip or spin coating, plasma coating, vacuum deposition, covalent, ionc, or van der Waals interactions, ink jet technology, or combinations thereof.
[0050] In Figure 3B, the sensing element is immobilized in a polymeric matrix and the polymer matuix is attached to the distal end of the optical fiber using, for example, adhesives, dip or spin coating, plasma coating, injection molding, ink jet technology, covalent, ionic, or van der Waals interactions, a mechanical connector or combinations thereof. In a prefewed embodiment, reactive groups of the polymer matrix and/or protein are used to covalently bond the sensing element directly to the optical fiber, such as for example by introducing amine groups on the surface of a glass or silica fiber. In Figure 3C, a plastic or polymer sleeve fits over the distal end of the optical fiber and seines to house and protect the sensing element. The sensing element is entrapped in or attached to a polymer matrix.
The polymer matrix containing the sensing element can be introduced into the sleeve either by injection, pouring, or dipping and can then be cross-linked or polymerized within the sleeve.
2 5 Alternatively, the sensing element may be polyrnenzed within the sleeve prior to insertion of the fiber optic. Figure 3D shows the optical fiber held within the inside of the needle. The needle may have a modified bevel to control piercing depth and/or a side port to permit access of the analyte to the sensing element contained in the needle. The sensing element inside the needle may be attached directly to the optical fiber using any of the methods described in the discussion of figures 3A, 3B, or 3C or, alternatively, may have only mechanical contact with the fiber. The attaclnnent schemes shown in Figure 3 are preferred embodiments and may be used either individually or in combination.
[0051] Figure 4 shows a preferred embodiment of a wearable optical biosensor.
The tip, 21, is a steel needle approximately 1 - 10 mm in length, containing within it the sensing element, 6, immobilized onto an optical fiber, 22. The fiber, tip, and needle assembly is centered in a plastic mount, 24. The tip, containing the optical fiber and the sensing element, is inserted perpendicularly into the shin of a patient so that the chemistry at the end of the fiber resides in either the intradennal or subcutaneous space. Adhesive ring 25 then holds the plastic mount plus needle assembly in place. The optical system 2, then clamps over the plastic assembly, with the connector 26 interfacing the optical fiber 22 with the optical system. The optical system can be designed, for example, according to either optical embodiment 2a or 2b. Excitation sources may consist of, but are not limited to, for example arc lamps, laser diodes, or LEDs. Detectors may consist of, but are not limited to, for example, photodiodes, CCD chips, or photomultiplier tubes.
[0052] The following examples illustrate certain prefeiTed embodiments of the instant ~' 0 invention, and are merely intended to be illustrative of exemplary embodiments. Labeled mutated binding proteins with fluorophore reporter probes are used herein in accordance with the procedure set forth by Cass et al., Ancrl. ClTem. 1994, 66, 3840-3847, or as otherwise described.

5 [0053] According to one embodiment of the present invention, glucose galactose binding protein (GGBP) was used with a triple mutation including a cysteine substituted for an glutamic acid at position 149, an arginine substituted for an alanine at position 213 and a serine substituted for leucine at position 238 (E149C/A213R/L238S). The protein was labeled at the 149 position with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD amide)oxy. This mutated GGBP
(E149C/A213R/L238S) is specific for glucose, and the reporter group undergoes a fluorescence intensity change in response to glucose binding.
[0054] A multicoated or multilayer matrix was prepared as follows. A core matrix was formed by mixing 1 part dye-labeled binding protein (15 uM in PBS buffer, pH
7.4, prepared as described in PCT/US03/00203) with 2 to 4 pacts 3 wt % alginate (v/v) in a scintillation vial and vortexing at slow speed. 3 mL of the resulting protein-alginate mixture was placed in a syringe and infused at a rate of 10 mL/hr into 200 ml of 1 M CaCh on a mixer, theret~y forming beads of about 0.4 to 1.5 111111 111 diameter. The beads were mixed in CaCh solution on the mixer for 15- 60 minutes. A contailunent layer was then formed by placing the beads from above in a solution of poly-L-lysine 0.01 %w/v in water, approximately 10 mL, for 1 hour, then drying the poly-lysine coated beads on an absorbent towel for 15 to 30 minutes. At this point the sensor was ready to be used.
[0055] The fiber used in this embodiment was a bifurcated fiber optic. It contained six 400um fibers arranged around a central 400 um fiber. The six fibers were used as the excitation conduit and the central fiber as the detection conduit. The total diameter of the 2 0 fiber was 1.4 lnln. Once the fiber was polished, Loctite 4011 medical grade glue was used to adhere the sensing element to the distal end of the fiber optic. The proximal end of the fiber was bifurcated, with one al~ln going to an excitation source and the other arln going to a detector. A 470 lun LED was used as the excitation source, and a commercial fluorescence spectrometer was used as the electromagnetic energy detector. The emission intensity at 540 2 5 nln was then measured.

[0056] W a trial, the distal end and sensing element of a biosensor formed in this manner was inserted tluough a 13 gauge needle into the side of an anesthetized pig, approximately 1-~ 11ll71 ulldel' the skin. Alternating solutions of lactated ringer's with and without 10%
dextrose were infused through the ear vein of the pig to increase and decrease the pig's glucose levels in a controllable fashion. At internals, blood samples were pulled from the versa cava of the pig tluough a tlwoat catheter, and blood sugar readings were tested on a handheld blood glucose meter. The fluorescence intensity of the biosensor was obsem~ed to track changing glucose levels in the anesthetized pig, as shown in Figure 5.

l0 [0057] In another embodiment, the binding protein was glucose galactose binding protein (GGBP), with a cysteine substituted for an glutamic acid at position 149, an arginine substituted for an alanine at position 213 and a serine substituted for leucine at position 238 (E149C/A213R/L238S). The protein was labeled at the 149 position with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD
amide). The biosensor was prepared by inserting the tip of a 400 micron core diameter fiber into a shoat piece of catheter tubing, and allowing the catheter tubing to overhang the fiber tip by 0.1 - 1 mm. The fiber comprised a silica core, silica cladding, and polyimide buffer.
The fiber diameter was 400/440/470 microns, where the slashes denote diameters measured fiom the core/cladding/buffer exteriors.
2 0 [0058] The immobilization matrix eras a crosslinl:ed alginate-based hydrogel, prepared by covalently crosslinking PronovaTM UP LVG alginate tlwough the carL~oxyls with adipic acid dihydrazide (AAD) via carbodiimide chemistry. PronovaTM UP LVG was selected in this embodiment for its low viscosity and high guluronic to mannuronic ratio. A 2%
alginate solution was prepared by dissolving 1 gram of alginate in 50 mL 0.1 M MES
buffer (pH 6.5) 2 5 and then adding 110 mg of AAD and 79 mg of hydroxybenzotriazole (HOBt).
The solution was stored at 4 °C until used. To the alginate solution, 145 mg of 1-ethyl-3- (3-dimethylamino-propyl) carbodiimide (EDC) was added per 10 mL of solution, using a dual-syringe mixing technique. The alginate, AAD, HOBt, EDC mixture was aspirated into a 1 mL syringe, and a blunt 30 gauge needle was attached to the syringe. The needle was primed, and then the tip was inseuted into the catheter tubing mold on the optical fiber. The catheter tubing on the fiber was filled, ensuring good contact between the tip of the fiber optic and the alginate matrix. The matrix was allowed to cross-link for 15 minutes, and then the fiber tip and matrix assembly were transfeiTed to a 0.1 M, 6.5 pH MES
solution, where they were stored for 2 hours. At the end of the two hours, the sensing tips were placed in excess phosphate buffer solution (PBS, 0.0027 M potassium chloride, 0.137 sodium chloride, pH 7.4 verhere they were stored a minimum of 30 minutes to quench the reaction.
[0059 To attach binding protein, the tips were incubated in a solution of labeled GGBP
in PBS buffer [NBD-E149C/A213R/L238S GGBP] (53 uM, 50 uL) for approximately 8 hours. The sensors were protected from ambient light during incubation. After 8-24 hours of incubation, 50 uL of EDC/NHS (200 mM/50 mM) was then added to the incubation tube.
After 40 minutes, the sensor tips were removed and placed in 50 uL of 1 M, pH
8.5 ethanolamine to quench the reaction. After 20 minutes in the ethanolamine solution, the sensor tips were transfeiTed to PBS solution, where they v~ere allowed to sit for at least 24 hours while um~eacted protein diffused out. The sensors were then transferred to fresh PBS
and stored in the dark until ready to use.
2 0 [0060] The fiber in this example was a single, 400 um core multimode finer (silica core, silica cladding, polyimide buffer). Since in this embodiment the same fiber transmits both the excitation and luminescence signal, diclwoic optics were used to separate the luminescence from the excitation, as shown in Figure 2A. Excitation was with a 4701ll11 LED. A commercial dichroic filter was used to reflect the 470 mn excitation towards the 2 5 input end of the fiber and transmit the fluorescence, centered at 550 mn, to the detector.
Glass aspheric lenses were used both for beam collimation and to focus light into the fibers and onto the detectors. Scattered excitation was further removed from the detector using a 550 mn bandpass filter. SMA connectors permitted rapid connection and disconnection of the fiber optic sensors. The electromagnetic energy detector of this embodiment was a single photon counting photomultiplier tube. Data acquisition was perfomned on a laptop computer communicating with the detector tln-ough an RS-232 cotmection [0061] FIG 6: In a trial, the distal end and sensing element of a biosensor formed in this manner was inserted into solutions of porcine serum containing different glucose concentrations. All porcine semm solutions were filtered tlwough a 200 micron filter, and glucose levels in the solutions were measured on a clinical analyzer. Figure 6 illustrates the in oitr~o performance of the sensor. The initial glucose level in the semm was measured to be 56 mg/dL. Set~um samples at 150 and 300 mg/dL were prepared Lay spiking concentrated 1M
glucose in PBS into serum aliquots.
EhAMPLE 3 [0062] In another embodiment of the present invention, a biosensor was formed by covalent attaclunent of a thin film to the surface of an optical fiber. The binding protein was glucose galactose binding protein (GGBP), with a cysteine substituted for a glutamic acid at position 149, an arginine substituted for an alanine at position ? 13 and a serine substituted for leucine at position 238 (E149C/A213R/L238S). The protein was labeled at the 149 position with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine 2 0 (IANBD amide).
[0063] The biosensor was prepared by covalent attaclnnent of an alginate matrix to the amine-functionalized surface of a silica fiber. The fiber comprised a silica core, silica cladding, and polyimide buffer. The fiber diameter was 400/440/470 microns, where the slashes denote diameters measured from the core/cladding/buffer exteriors.
L 5 [0064] The polyimide buffer was removed fiom the tip of the optical fiber by exposing the last few millimeters of the fiber to a torch for approximately 1 - ?
seconds. The residual polyimide was then wiped away. The tip with the buffer removed was then placed in 1 M
sulfuric acid for 1 hour. Tips were then rinsed with distilled water, placed in ethanol for 15 minutes, and then submerged in anhydrous toluene for 15 minutes. The cleaned tips were then placed in warm (60° C) aWydrous toluene containing 1% 3-aminopropyltriethoxysilane (APTES) and allowed to react for 5 minutes. The tips were then removed from the APTES
solution and washed with ethanol for 15 minutes. At the end of this process, the presence of amine groups on the surface of the fiber was verified by photoelectron spectroscopy.
[0065] An alginate matrix was then applied to the amine-functionalized fiber surface as follows. The in unobilization matuix was a crosslinl:ed alginate-based hydrogel, prepared by covalently crosslinking PronovaTM UP LVG alginate, selected for its low viscosity and high guluronic to mannuronic ratio, tluough the carboxyls with adipic acid dihydrazide (AAD) via carbodiimide chemistry. A 2% alginate solution was prepared by dissolving 1 gram of alginate in 50 mL 0.1 M MES buffer (pH 6.5) and then adding 110 mg of AAD and 79 mg of hydroxybenzotriazole (HOBt). A 0.5 mL aliquot of this solution was then mixed with 10 mg of EDC in 50 uL of MES buffer using a dual-syringe mixing technique. The total volume of the solution was approximately O.SSmL. The alginate, AAD, HOBt, EDC mixture was then transferred to microcentrifuge vials, and the APTES-functionalized fiber tips were submerged in the alginate solution for 3-4 minutes or until the matrix began to solidify. The tips were then removed from the alginate solution, allowed to continue reacting in air for '' 0 approximately 1-10 minutes, and then transferred to O.1M, 6.5 pH MES
buffer. The tips were allowed to sit in the MES buffer for 2 hours, and then they were quenched in excess phosphate buffer solution (PBS, 0.0027 M potassium chloride, 0.137 sodium chloride, pH
7.4) for a minimum of 30 minutes.
[0066] To attach the binding protein, the tips were incubated in a solution of labeled ~ 5 GGBP in PBS buffer [NBD-E149C/A213R/L238S GGBP] (20 - 60 uM, 50 uL) for several hours. The sensors were protected from ambient light during incubation. After approximately 2 - 8 hour of incubation, 50 uL of EDC/NHS (200 mM/50 mM) were added to the incubation tube. After 5 - 40 minutes, the sensor tips were removed and placed in 50 uL
of 1M, pH 8.5 ethanolamine to quench the reaction. After 20 minutes in the ethanolamine solution, the sensor tips were transferred to PBS solution, where they were allowed to sit for at least 8 hours while unreacted protein diffused out. The sensors were then transferred to fi~esh PBS and stored in the dark until ready to use.
[0067] In a trial of the above described embodiment, the optical reader was the same as descrit~ed in the previous example, with the exception that the 470 run excitation was modulated using a solenoid-driven shutter. In addition to interfacing with and controlling the shutters and detectors, the software permitted timed acquisition of fluorescence reading, graphical display of the results, and data analysis and calibration algoritlnns.
[0068] The distal end and sensing element of a biosensor formed in this mamier was then inserted into the side of an anesthetized pig. Insertion was done by inserting the fiber either intradeunally or subcutaneously through a hole in the skin formed by a 18 - 24 gauge needle.
Alternating solutions of lactated ringer's with and without 10% dextrose were infused tlwough the ear vein of the pig to increase and decrease the pig's glucose levels in a controllable fashion. At intervals, blood samples were pulled from the versa cava of the pig tlu-ough a tlwoat catheter, and blood sugar readings were tested on a handheld blood glucose meter. The fluorescence intensity of the biosensor was observed to track changing blood 2 0 glucose levels in the anesthetized pig, as shown in Figure 7.

[0069] In another embodiment of the invention, dual wavelength detection with an internal optical reference group was performed. The binding protein was glucose galactose Minding protein (GGBP), with a cysteine substituted for a glutamic acid at position 149, an 5 arginine substituted for an alanine at position ? 13 and a serine substituted for leucine at position 238 (E149C/A213R/L238S). The protein was labeled at the 149 position with the repouter group N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine (IANBD amide). The reference group was Texas Red~ C2 maleimide attached to GGBP with a cysteine substituted for a glutamic acid at position 149 (TR-E149C
GGBP). Over the physiological range of glucose concentrations, the luminescence from TR-E149C GGBP is substantially unchanged, and thus TR-E149C GGBP serves as an internal reference for the signal from the analyte-dependent binding protein and reporter group (NBD-E149C/A213R/L?38S GGBP].
[0070] The biosensor was prepared by inserting the tip of a 400 micron core diameter fiber into a short piece of catheter tubing, allowing the catheter tubing to overhang the fiber tip by 0.1 - 0.5 mm. The fiber comprised a silica core, silica cladding, and polyimide buffer.
The fiber diameter was 400/440/470 microns, where the slashes denote diameters measured from the core/cladding/buffer exteriors.
[0071] The immobilization matrix was a crosslinked alginate-based hydrogel, prepared by covalently crosslinhing PronovaTM UP LVG alginate, selected for its low viscosity and l 5 high guluronic to mammronic ratio, tlwough the carboxyls with adipic acid dihydrazide (AAD) via carbodiimide chemistry. A 2% alginate solution was prepared by dissolving 1 gram of alginate in 50 mL 0.1 M MES buffer (pH 6.5) and then adding 110 mg of AAD and 79 mg of hydroxybenzotriazole (HOBt). The solution was stored at 4 °C
until used. Using a dual-syringe mixing technique, a 0.5 mL aliquot of the alginate solution was then mixed with a 50 uL MES solution containing 10 mg of 1-ethyl-3- (3-dimethylamino-propyl) carbodiimide (EDC) and 90 yL of 60 ~M TR-E149C GGBP. The alginate, AAD, HOBt, EDC, TR-E149C mixture was aspirated into a 1 mL syringe, and a blunt 30 gauge needle was attached to the syringe. The needle was primed, and then the tip was inserted into the catheter tubing mold on the optical fiber. The catheter tubing on the fiber was filled, ensuring 2 5 good contact between the tip of the fiber optic and the alginate matrix.
The matuix was allowed to cross-link for 15 minutes, and then the fiber tip and matrix assembly were transfewed to a 0.1 M, 6.5 pH MES solution, where they were stored for 2 hours. At the end of the two hours, the sensing tips were placed in excess phosphate buffer solution (PBS, 0.0027 M potassium chloride, 0.137 sodium chlouide, pH = 7.4) where they were stored a minimum of 30 minutes to quench the reaction.
[0072] To attach binding protein, the tips were incubated in a solution containing IANBD
labeled GGBP in PBS buffer NBD-E149C/A213R/L238S GGBP. During the incubation period, the sensors were protected from ambient light. After approximately 2 -8 hour of incubation, 50 uL of EDC/NHS (200 mM/50 ml\~ were added to the incubation tube. After 5 - 40 minutes, the sensor tips were removed and placed in 50 uL of 1 M, pH 8.5 ethanolamine to quench the reaction. After 20 minutes in the ethanolamine solution, the sensor tips were transfeiTed to PBS solution, where they were allowed to sit for at least 8 hours while um~eacted protein diffused out. The sensors were then transfeiTed to fresh PBS
and stored in the dark until ready to use.
[0073] In a trial of the above described embodiment, the fluorescence signal ~jas read using an optical system following the configuration illustrated in Figure 2A.
A 470 nm LED
(LS-450) was used for excitation, and two single photon counting photomultiplier tubes were used as electromagnetic energy detectors. A commercial diclwoic beamsplitter was used to reflect the 470 mn light from the electromagnetic energy emitter towards the fiber and to 2 0 transmit the luminescence signals from the reporter and reference groups towards the detectors. A second dich roic beamsplitter was used to separate the luminescence signals from the repouter and reference groups, directing the emission from NBD-E149C/A213R/L238S towards one detector and the emission from TR-E149C GGBP
towards the other detector. A 550 Illll bandpass filter in fi-ont of one detector and a 610 run bandpass 5 filter in front of the other detector were used to achieve further spectral resolution for NBD-E149C/A213R/L238S and TR-E149C GGBP, respectively.
2s [0074] In a trial, the distal end and sensing element of a biosensor formed in this mamer was inserted into solutioys of PBS buffer containing different levels of glucose. Glucose levels in the solutions were measured on a clinical analyzer. Figure 8 shows the sensor response to changing glucose levels. The 550 mn signal from the IANBD reporter group tracks changing glucose levels. The 610 run emission from the Texas Reds reporter group is substantially unchanged as glucose levels vary. However, in this embodiment, a portion of the reporter group's emission also occurs at 610 run. The detector in the optical system that tracks the 610 imn luminescence signal detects both the emission of the reference group and also the portion of the reporter group (IANBD) emission that occurs in this wavelength region. Since the contribution to the 610 mn signal from the repouter group is a constant fraction of the 550 mn signal, this contribution can be mathematically subtracted from the 610 mn signal to generate the signal due to the reference group alone. When this mathematical manipulation is performed, the 610 nm signal is substantially unchanging with glucose concentration as shown in Figure 8.
[00?5] While the invention herein disclosed has been described by means of specific embodiments and applications thereof, numerous modifications and variations can be made thereto by those skilled in the art without departing from the scope of the invention as set forth in the claims.

Claims (42)

1. A device for sensing a target analyte in a sample comprising:
an optical conduit having a proximal end and a distal end;
an optical system at the proximal end of the optical conduit comprising at least one electromagnetic energy emitter and at least one electromagnetic energy detector; and a sensing element in optical proximity to the distal end of the optical conduit comprising at least one binding protein adapted to bind with at least one target analyte and at least one reporter group associated with the binding protein, wherein the reporter group is adapted to undergo a luminescence change upon binding of the binding protein to the target analyte, and optionally, at least one reference group.
2. The device of claim 1, further comprising a tip.
3. The device of claim 2, wherein the sensing element is contained within the tip.
4. The device of claim 3, wherein the sensing element is attached to the inner surface of the tip and the tip is directly attached to the distal end of the optical conduit.
5. The device of claim 1, wherein the sensing element is directly attached to the distal end of the optical conduit.
6. The device of claim 1, further comprising one or more connectors.
7. The device of claim 6, wherein the sensing element is attached to the distal end of the optical conduit through a corrector.
8. The device of claim 1, wherein the sensing element is entrapped in or attached to a polymer matrix.
9. The device of claim 8, wherein the polymer matrix is directly attached to the distal end of the optical conduit.
10. The device of claim 8, wherein the polymer matrix is attached to the inner surface of a tip wherein the tip is directly attached to the distal end of the optical conduit.
11. The device of claim 8, wherein the polymer matrix is attached to the inner surface of a tip wherein the tip is directly attached to a connector that is directly attached to the distal end of the optical conduit.
12. The device of claim 1, wherein the sensing element is attached to a polymer chain.
13. The device of claim 12, wherein said polymer chain is attached to the distal end of the optical conduit.
14. The device of claim 12, wherein the polymer chain is attached to the inner surface of a tip wherein the tip is directly attached to the distal end of the optical conduit.
15. The device of claim 12, wherein the polymer chain is attached to the inner surface of a tip wherein the tip is directly attached to a connector that is directly attached to the distal end of the optical conduit.
16. The device of claim 6, wherein the optical system is attached to the proximal end of the optical conduit through the connector.
17. The device of claim 6, wherein the sensing element is attached to the distal end of the optical conduit through a corrector and the optical system is attached to the proximal end of the optical conduit through a connector.
18. The device of claims 16 and 17, further comprising a tip wherein the tip is attached to the distal end of the optical conduit through a connector.
19. The device of claim 1, wherein the optical conduit comprises at least one optical fiber.
20. The device of claim 1, wherein the electromagnetic energy emitter is selected from the group consisting of an arc lamp, light emitting diode, and laser diode.
21. The device of claim 1, wherein the electromagnetic energy detector is a photodiode, photomultiplier tube, or charge coupled device.
22. The device of claim 1, wherein said optical system further comprises optical elements adapted to distinguish multiple wavelengths.
23. The device of claim 22, wherein said optical elements further comprise optical filters, dichroic components, holographic components, or combinations thereof.
24. The device of claim 21, wherein said electromagnetic energy detector is adapted to detect energy emitted by said reporter group substantially continuously.
25. The device of claim 21 wherein said electromagnetic energy detector is adapted to detect energy emitted by said reporter group periodically.
26. The device of claim 1, wherein said optical system further comprises electrical or optoelectronic elements for modulation of the signal from the electromagnetic energy emitter.
27. The device of claim 1, wherein said optical system further comprises electrical or optoelectronic elements for modulation of the luminescence signal received by the electromagnetic energy detector.
28. The device of claim 1, wherein the optical system is adapted to measure the intensity of the luminescence signal.
29. The device of claim 1, wherein the optical system is adapted to measure the wavelength of the luminescence signal.
30. The device of claim 1, wherein the optical system is adapted to measure the lifetime of the luminescence signal.
31. The device of claim 1, wherein the optical system is adapted to measure the polarization of the luminescence signal.
32. The device of claim 1, wherein the optical system is adapted to measure the energy transfer efficiency of the reporter group.
33. The device of claim 2, wherein said tip further comprises a metal flame.
34. The device of claim 1, wherein at least one reference group is associated with a protein.
35. The device of claim 1, wherein said sensing element is further adapted to be inserted into or through the skin of a patient.
36. The device of claim1, wherein at least one reporter group and at least one reference group are excited at the same wavelengths.
37. The device of claim 1, wherein at least one reporter group and at least one reference group are excited at different wavelengths.
38. The device of claim 1, wherein the luminescence of at least one reporter group and at least one reference group is detected at different wavelengths.
39. The device of claim 1, wherein the luminescence of at least one reporter group and at least one reference group is detected at the same wavelengths.
40. The device of claim 1, wherein the reporter group comprises a pair of organic dyes chosen so that the energy transfer efficiency between the pair changes upon analyte binding.
41. The device of claim 1, wherein the reporter group comprises a pair of fusion proteins chosen so that the energy transfer efficiency between the pair changes upon analyte binding.
42. The device of claim 1, wherein the reporter group comprises an organic dye and a fusion protein chosen so that the energy transfer efficiency between the organic dye and the fusion protein changes upon analyte binding.
CA2546945A 2003-11-26 2004-11-12 Fiber optic device for sensing analytes Expired - Fee Related CA2546945C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/721,797 US7496392B2 (en) 2003-11-26 2003-11-26 Fiber optic device for sensing analytes
US10/721,797 2003-11-26
PCT/US2004/038487 WO2005054831A1 (en) 2003-11-26 2004-11-12 Fiber optic device for sensing analytes

Publications (2)

Publication Number Publication Date
CA2546945A1 true CA2546945A1 (en) 2005-06-16
CA2546945C CA2546945C (en) 2013-01-15

Family

ID=34591881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546945A Expired - Fee Related CA2546945C (en) 2003-11-26 2004-11-12 Fiber optic device for sensing analytes

Country Status (12)

Country Link
US (2) US7496392B2 (en)
EP (1) EP1692493B1 (en)
JP (1) JP5442931B2 (en)
CN (1) CN1902476B (en)
AT (1) ATE466276T1 (en)
AU (1) AU2004295684B2 (en)
BR (1) BRPI0416985A (en)
CA (1) CA2546945C (en)
DE (1) DE602004026910D1 (en)
NO (1) NO20062941L (en)
WO (1) WO2005054831A1 (en)
ZA (1) ZA200605239B (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
WO2002078512A2 (en) 2001-04-02 2002-10-10 Therasense, Inc. Blood glucose tracking apparatus and methods
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
EP2386758A1 (en) 2002-10-09 2011-11-16 Abbott Diabetes Care Inc. A method of pumping a predetermined dose of a medical fluid
US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
US7787923B2 (en) * 2003-11-26 2010-08-31 Becton, Dickinson And Company Fiber optic device for sensing analytes and method of making same
WO2005089103A2 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
JP5042820B2 (en) * 2004-05-14 2012-10-03 ベクトン・ディキンソン・アンド・カンパニー Articles with bioactive surfaces and methods for their solvent-free preparation
CA2595239C (en) * 2005-01-19 2016-12-20 Dermaspect Llc Devices and methods for identifying and monitoring changes of a suspect area on a patient
CN101180093B (en) 2005-03-21 2012-07-18 雅培糖尿病护理公司 Method and system for providing integrated medication infusion and analyte monitoring system
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7620437B2 (en) 2005-06-03 2009-11-17 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7740588B1 (en) * 2005-06-24 2010-06-22 Michael Sciarra Wireless respiratory and heart rate monitoring system
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
US7583190B2 (en) 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
CA2649535A1 (en) * 2006-04-20 2007-11-01 Becton, Dickinson And Company Thermostable proteins and methods of making and using thereof
US7809441B2 (en) 2006-05-17 2010-10-05 Cardiac Pacemakers, Inc. Implantable medical device with chemical sensor and related methods
US20080071158A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
EP1944599A3 (en) 2007-01-11 2008-11-12 Fujifilm Corporation Fluorescence analysis apparatus
US8088097B2 (en) 2007-11-21 2012-01-03 Glumetrics, Inc. Use of an equilibrium intravascular sensor to achieve tight glycemic control
EP2989975B1 (en) * 2007-02-06 2018-06-13 Medtronic MiniMed, Inc. Optical systems and methods for rationmetric measurement of blood glucose concentration
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
EP2113091A1 (en) * 2007-02-23 2009-11-04 Becton, Dickinson and Company, Wagner, Jaconda Optical fiber connector
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
WO2008141241A1 (en) 2007-05-10 2008-11-20 Glumetrics, Inc. Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement
JP5453248B2 (en) * 2007-05-22 2014-03-26 ベクトン・ディキンソン・アンド・カンパニー Dyes with a ratiometric fluorescence response to detect metabolites
US9042967B2 (en) 2008-05-20 2015-05-26 University Health Network Device and method for wound imaging and monitoring
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
ATE507768T1 (en) * 2008-10-02 2011-05-15 Eyesense Ag IMPLANTATION DEVICE FOR METABOLITE SENSORS
ES2530450T3 (en) 2008-10-02 2015-03-03 Eyesense Ag Implantable sensor element
US8437821B2 (en) * 2009-01-06 2013-05-07 Panasonic Corporation Non-invasive body information measurement apparatus
US9375529B2 (en) 2009-09-02 2016-06-28 Becton, Dickinson And Company Extended use medical device
CA3149758A1 (en) 2009-01-12 2010-07-15 Becton, Dickinson And Company Infusion set and/or patch pump having at least one of an in-dwelling rigid catheter with flexible features and/or a flexible catheter attachment
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US8467972B2 (en) 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
WO2010135006A2 (en) * 2009-05-22 2010-11-25 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The Portland State University Sensitive gas-phase fluorimeter at ambient pressure for nitrogen dioxide
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
WO2011011739A2 (en) 2009-07-23 2011-01-27 Abbott Diabetes Care Inc. Real time management of data relating to physiological control of glucose levels
US8939928B2 (en) * 2009-07-23 2015-01-27 Becton, Dickinson And Company Medical device having capacitive coupling communication and energy harvesting
US9314195B2 (en) 2009-08-31 2016-04-19 Abbott Diabetes Care Inc. Analyte signal processing device and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
US10092691B2 (en) 2009-09-02 2018-10-09 Becton, Dickinson And Company Flexible and conformal patch pump
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
EP2483679A4 (en) * 2009-09-30 2013-04-24 Glumetrics Inc Sensors with thromboresistant coating
US8741591B2 (en) 2009-10-09 2014-06-03 The Research Foundation For The State University Of New York pH-insensitive glucose indicator protein
US8467843B2 (en) 2009-11-04 2013-06-18 Glumetrics, Inc. Optical sensor configuration for ratiometric correction of blood glucose measurement
JP2013519483A (en) * 2010-02-19 2013-05-30 ライトシップ メディカル リミテッド Subcutaneous glucose sensor
EP2545373B1 (en) * 2010-03-11 2022-08-24 Medtronic Minimed, Inc. Measuring analyte concentration incorporating temperature and ph correction
CN103260501B (en) 2010-10-06 2015-09-02 普罗弗萨股份有限公司 Tissue integration sensor
US20120123230A1 (en) * 2010-10-13 2012-05-17 Tandem Diebetes Care, Inc. Analyte monitoring systems and methods of use
US8795230B2 (en) 2010-11-30 2014-08-05 Becton, Dickinson And Company Adjustable height needle infusion device
US9950109B2 (en) 2010-11-30 2018-04-24 Becton, Dickinson And Company Slide-activated angled inserter and cantilevered ballistic insertion for intradermal drug infusion
US8814831B2 (en) 2010-11-30 2014-08-26 Becton, Dickinson And Company Ballistic microneedle infusion device
CN102160777B (en) * 2011-03-10 2013-07-03 中国人民解放军第三军医大学第一附属医院 Body fluid bioinformation fiber dynamic testing system
WO2013070794A2 (en) 2011-11-07 2013-05-16 Abbott Diabetes Care Inc. Analyte monitoring device and methods
DE102012201892A1 (en) * 2012-02-09 2013-08-14 Robert Bosch Gmbh Determining the blood glucose level of a patient using an implantable sensor and an electrical functional patch
EP2831583B1 (en) 2012-03-28 2019-12-18 Becton, Dickinson and Company Hydrogel adhesion to molded polymers
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
WO2014058993A2 (en) 2012-10-12 2014-04-17 Becton, Dickinson And Company Case with embedded electronics to provide interface between glucose sensor and smartphone
WO2014074621A1 (en) * 2012-11-07 2014-05-15 Glumetrics, Inc. Dry insertion and one-point in vivo calibration of an optical analyte sensor
US10466247B2 (en) 2012-11-20 2019-11-05 Becton, Dickinson And Company System and method for diagnosing sensor performance using analyte-independent ratiometric signals
US10327685B2 (en) 2012-12-20 2019-06-25 Becton, Dickinson And Company System and method for using multiple sensor calibration methods
CA2898999C (en) 2013-01-22 2018-10-23 Becton, Dickinson And Company Reduced size optical coupler for fluorescence detection
GB201321245D0 (en) * 2013-12-02 2014-01-15 Univ Ireland Dublin Gas sensor
EP2967453B1 (en) * 2013-03-14 2020-05-13 Becton, Dickinson and Company Continuous glucose monitoring on-body sensor having a visual display
CA2904031A1 (en) 2013-03-14 2014-10-02 Profusa, Inc. Method and device for correcting optical signals
CN105307559B (en) 2013-06-06 2020-06-05 普罗菲尤萨股份有限公司 Apparatus and method for detecting optical signals from implanted sensors
US10379125B2 (en) 2013-12-27 2019-08-13 Becton, Dickinson And Company System and method for dynamically calibrating and measuring analyte concentration in diabetes management monitors
ES2920777T3 (en) * 2014-02-17 2022-08-09 Eaton Intelligent Power Ltd Oxygen sensor comprising a tip-coated optical fiber with a large diameter
CN103860145A (en) * 2014-03-27 2014-06-18 黄鹏 Implantation type detection device on the basis of fluorescence detection method
WO2015146499A1 (en) * 2014-03-28 2015-10-01 テルモ株式会社 Fluorescent light sensor
US10004845B2 (en) 2014-04-18 2018-06-26 Becton, Dickinson And Company Split piston metering pump
WO2015179288A1 (en) 2014-05-19 2015-11-26 University Of South Florida Systems and methods for analyzing liquids
US9416775B2 (en) 2014-07-02 2016-08-16 Becton, Dickinson And Company Internal cam metering pump
PT3171765T (en) 2014-07-24 2021-10-27 Univ Health Network Collection and analysis of data for diagnostic purposes
KR102496129B1 (en) 2014-08-01 2023-02-07 엠벡타 코포레이션 Continuous glucose monitoring injection device
WO2016029288A1 (en) * 2014-08-26 2016-03-03 Narwhal Analytical Corporation (Ontario Corporation Number 002408580) Mini-fluidics cassette for colorimetric nutrient analysis and a method of using same
US10006882B2 (en) 2014-11-21 2018-06-26 EnLiSense, LLC Biosensing system and methods using electron-ionic mechanisms at fluid-sensor interfaces
CN104523284B (en) * 2014-12-20 2016-05-18 佛山市南海区欧谱曼迪科技有限责任公司 A kind of blood sugar measuring system based on holographic nanometer detection and the extraction of micro-wound tissue liquid
JP6511303B2 (en) * 2015-03-13 2019-05-15 テルモ株式会社 Sensor
WO2016182348A1 (en) * 2015-05-11 2016-11-17 Samsung Electronics Co., Ltd. Needle for biosensor and bio sensor including the same
US10716500B2 (en) 2015-06-29 2020-07-21 Cardiac Pacemakers, Inc. Systems and methods for normalization of chemical sensor data based on fluid state changes
EP3380827B1 (en) * 2015-11-23 2023-11-29 Revvity Health Sciences, Inc. Hollow polymer fiber optic system for single analyte and multiplexed analyte detection
US10850046B2 (en) * 2016-03-28 2020-12-01 Becton, Dickinson And Company Cannula locator device
US10835718B2 (en) 2016-03-28 2020-11-17 Becton, Dickinson And Company Cannula with light-emitting optical fiber
US11478150B2 (en) 2016-03-28 2022-10-25 Becton, Dickinson And Company Optical fiber sensor
CN109997198B (en) 2016-10-12 2023-08-04 英佰达公司 Comprehensive disease management system
US11331018B2 (en) 2016-12-22 2022-05-17 Profusa, Inc. System and single-channel biosensor for and method of determining analyte value
CN108968976B (en) 2017-05-31 2022-09-13 心脏起搏器股份公司 Implantable medical device with chemical sensor
CN109381195B (en) 2017-08-10 2023-01-10 心脏起搏器股份公司 Systems and methods including electrolyte sensor fusion
CN109419515B (en) 2017-08-23 2023-03-24 心脏起搏器股份公司 Implantable chemical sensor with staged activation
CN109864746B (en) 2017-12-01 2023-09-29 心脏起搏器股份公司 Multimode analyte sensor for medical devices
CN109864747B (en) 2017-12-05 2023-08-25 心脏起搏器股份公司 Multimode analyte sensor optoelectronic interface
BR112021009861A2 (en) * 2018-11-21 2021-08-31 Acies Medical Llc DETECTION SYSTEMS AND METHODS FOR MEDICAL DEVICES
CN110296970A (en) * 2019-08-02 2019-10-01 普乐药业有限公司 Portable blood sugar measuring instrument

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548907A (en) 1983-09-14 1985-10-22 Allied Corporation Fluorescent fluid determination method and apparatus
US5354825A (en) 1985-04-08 1994-10-11 Klainer Stanley M Surface-bound fluorescent polymers and related methods of synthesis and use
US4981779A (en) 1986-06-26 1991-01-01 Becton, Dickinson And Company Apparatus for monitoring glucose
US5001054A (en) 1986-06-26 1991-03-19 Becton, Dickinson And Company Method for monitoring glucose
JP2628355B2 (en) * 1987-09-22 1997-07-09 バクスター、インターナショナル、インコーポレイテッド Fiber optic probe connector for physiological measurement devices
US4925268A (en) 1988-07-25 1990-05-15 Abbott Laboratories Fiber-optic physiological probes
US4907857A (en) 1988-07-25 1990-03-13 Abbott Laboratories Optical fiber distribution system for an optical fiber sensor
JPH0257950A (en) * 1988-08-24 1990-02-27 Terumo Corp Probe for measuring ion concentration
IL89159A0 (en) * 1989-02-02 1989-09-10 Optical Chemical Tech Oct Medical probe
US6010867A (en) * 1989-04-19 2000-01-04 Ibiden Co., Ltd. Reagent for biomaterials assay, preparation method thereof, and assay method
DE3919696A1 (en) * 1989-06-16 1991-01-10 Bayer Ag POLYURETHANE-BASED REACTIVE ADHESIVES
FR2650076B1 (en) * 1989-07-20 1991-10-04 Commissariat Energie Atomique OPTICAL FIBER ACTIVE CHEMICAL SENSOR AND MANUFACTURING METHOD THEREOF
US5176881A (en) * 1989-08-11 1993-01-05 The University Of Tennessee Research Corporation Fiber optic-based regenerable biosensor
EP0413499A3 (en) 1989-08-16 1991-07-24 Puritan-Bennett Corporation Sensor element and method for making the same
US5342789A (en) * 1989-12-14 1994-08-30 Sensor Technologies, Inc. Method and device for detecting and quantifying glucose in body fluids
US6040194A (en) 1989-12-14 2000-03-21 Sensor Technologies, Inc. Methods and device for detecting and quantifying substances in body fluids
US5127405A (en) * 1990-02-16 1992-07-07 The Boc Group, Inc. Biomedical fiber optic probe with frequency domain signal processing
US5143066A (en) 1990-05-08 1992-09-01 University Of Pittsburgh Optical fiber sensors for continuous monitoring of biochemicals and related method
CA2053449A1 (en) * 1990-10-16 1992-04-17 Henry K. Hui Optical fiber ph microsensor and method of manufacture
US5154890A (en) 1990-11-07 1992-10-13 Hewlett-Packard Company Fiber optic potassium ion sensor
US5244813A (en) * 1991-01-25 1993-09-14 Trustees Of Tufts College Fiber optic sensor, apparatus, and methods for detecting an organic analyte in a fluid or vapor sample
US5377676A (en) 1991-04-03 1995-01-03 Cedars-Sinai Medical Center Method for determining the biodistribution of substances using fluorescence spectroscopy
US5340715A (en) * 1991-06-07 1994-08-23 Ciba Corning Diagnostics Corp. Multiple surface evanescent wave sensor with a reference
CA2069537A1 (en) * 1991-06-07 1992-12-08 Thomas A. Cook Multiple output referencing system for evanescent wave sensor
JP3107649B2 (en) * 1991-12-20 2000-11-13 イビデン株式会社 Fluorescent immunoassay
US6256522B1 (en) 1992-11-23 2001-07-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Sensors for continuous monitoring of biochemicals and related method
JP3305398B2 (en) * 1993-03-31 2002-07-22 三菱レイヨン株式会社 Optical fiber sensor
US5341805A (en) 1993-04-06 1994-08-30 Cedars-Sinai Medical Center Glucose fluorescence monitor and method
US5512492A (en) * 1993-05-18 1996-04-30 University Of Utah Research Foundation Waveguide immunosensor with coating chemistry providing enhanced sensitivity
US5552272A (en) 1993-06-10 1996-09-03 Biostar, Inc. Detection of an analyte by fluorescence using a thin film optical device
US5569911A (en) 1993-07-19 1996-10-29 General Electric Company Fiber optic system for remote fluorescent sensing using excitation and return fibers
JPH07110330A (en) * 1993-09-01 1995-04-25 Bio Sensor Kenkyusho:Kk Optical sensor
US5496997A (en) 1994-01-03 1996-03-05 Pope; Edward J. A. Sensor incorporating an optical fiber and a solid porous inorganic microsphere
US5515864A (en) 1994-04-21 1996-05-14 Zuckerman; Ralph Method and apparatus for the in vivo measurement of oxygen concentration levels by the indirect determination of fluoescence lifetime
US5605152A (en) 1994-07-18 1997-02-25 Minimed Inc. Optical glucose sensor
AT403961B (en) 1995-03-17 1998-07-27 Avl Verbrennungskraft Messtech OPTOCHEMICAL MEASURING SYSTEM WITH A FLUORESCENCE SENSOR
US5628310A (en) 1995-05-19 1997-05-13 Joseph R. Lakowicz Method and apparatus to perform trans-cutaneous analyte monitoring
US5656241A (en) 1995-09-07 1997-08-12 Optical Sensors Incorporated Method for manufacturing fiber optic sensors
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
US5747349A (en) 1996-03-20 1998-05-05 University Of Washington Fluorescent reporter beads for fluid analysis
US5938595A (en) * 1996-05-24 1999-08-17 The Regents Of The University Of California Fiber optic D dimer biosensor
US6111248A (en) 1996-10-01 2000-08-29 Texas Instruments Incorporated Self-contained optical sensor system
EP0834734A3 (en) 1996-10-01 1998-09-16 Texas Instruments Inc. Optical sensor
JPH10132747A (en) 1996-10-01 1998-05-22 Texas Instr Inc <Ti> Small-sized integrated sensor platform
US5946083A (en) 1997-10-01 1999-08-31 Texas Instruments Incorporated Fixed optic sensor system and distributed sensor network
ES2227880T3 (en) * 1997-08-09 2005-04-01 Roche Diagnostics Gmbh ANALYSIS DEVICE FOR PERFORMING LIVE ANALYSIS IN A PATIENT'S BODY.
US5900512A (en) 1997-09-11 1999-05-04 Albemarle Corporation Oxidation process
US6081736A (en) 1997-10-20 2000-06-27 Alfred E. Mann Foundation Implantable enzyme-based monitoring systems adapted for long term use
AU760743B2 (en) 1997-12-31 2003-05-22 Duke University Biosensor
US6289229B1 (en) * 1998-01-20 2001-09-11 Scimed Life Systems, Inc. Readable probe array for in vivo use
US6020207A (en) * 1998-06-17 2000-02-01 World Precision Instruments, Inc. Optical analysis technique and sensors for use therein
US6157442A (en) 1998-06-19 2000-12-05 Microsense International Llc Micro optical fiber sensor device
DE69941085D1 (en) * 1998-07-17 2009-08-20 Univ Maryland MANIPULATED PROTEINS FOR ANALYSIS PROOF
US6535753B1 (en) 1998-08-20 2003-03-18 Microsense International, Llc Micro-invasive method for painless detection of analytes in extra-cellular space
US6197257B1 (en) 1998-08-20 2001-03-06 Microsense Of St. Louis, Llc Micro sensor device
AU770909B2 (en) 1998-08-26 2004-03-04 Sensors For Medicine And Science, Inc. Optical-based sensing devices
US6304766B1 (en) 1998-08-26 2001-10-16 Sensors For Medicine And Science Optical-based sensing devices, especially for in-situ sensing in humans
US6936044B2 (en) * 1998-11-30 2005-08-30 Light Bioscience, Llc Method and apparatus for the stimulation of hair growth
US6432723B1 (en) 1999-01-22 2002-08-13 Clinical Micro Sensors, Inc. Biosensors utilizing ligand induced conformation changes
US6704587B1 (en) 1999-04-01 2004-03-09 Spectrx, Inc. Dual function assay device
US6584214B1 (en) * 1999-04-23 2003-06-24 Massachusetts Institute Of Technology Identification and verification using complex, three-dimensional structural features
CA2376128C (en) 1999-06-04 2009-01-06 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6366793B1 (en) * 1999-09-10 2002-04-02 Beckman Coulter, Inc. Minimally invasive methods for measuring analtes in vivo
JP2001255326A (en) * 2000-01-31 2001-09-21 Pen State Res Found:The Inquiry related to change of content in hermetically sealed container
WO2001075450A2 (en) * 2000-04-04 2001-10-11 The Regents Of The University Of California Fluorescent lifetime assays for non-invasive quantification of analytes
US6540675B2 (en) 2000-06-27 2003-04-01 Rosedale Medical, Inc. Analyte monitor
GB0025147D0 (en) 2000-10-13 2000-11-29 Torsana Diabetes Diagnostics A Optical sensor for in situ measurement of analytes
AU2002367906A1 (en) * 2001-10-02 2003-12-12 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Internal biochemical sensing device
US20030232383A1 (en) 2001-11-02 2003-12-18 Sylvia Daunert Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein
US20030153026A1 (en) * 2002-01-04 2003-08-14 Javier Alarcon Entrapped binding protein as biosensors
US7064103B2 (en) 2002-01-04 2006-06-20 Becton, Dickinson And Company Binding protein as biosensors
US6855556B2 (en) * 2002-01-04 2005-02-15 Becton, Dickinson And Company Binding protein as biosensors
AU2003287735A1 (en) 2002-11-12 2004-06-03 Argose, Inc. Non-invasive measurement of analytes
US20040234962A1 (en) * 2003-05-02 2004-11-25 Javier Alarcon Multicoated or multilayer entrapment matrix for protein biosensor

Also Published As

Publication number Publication date
JP5442931B2 (en) 2014-03-19
ATE466276T1 (en) 2010-05-15
CA2546945C (en) 2013-01-15
US7792561B2 (en) 2010-09-07
US20080198358A1 (en) 2008-08-21
JP2007513333A (en) 2007-05-24
CN1902476A (en) 2007-01-24
WO2005054831A1 (en) 2005-06-16
EP1692493B1 (en) 2010-04-28
AU2004295684A1 (en) 2005-06-16
NO20062941L (en) 2006-08-24
CN1902476B (en) 2013-12-04
AU2004295684B2 (en) 2010-01-21
US7496392B2 (en) 2009-02-24
DE602004026910D1 (en) 2010-06-10
EP1692493A1 (en) 2006-08-23
BRPI0416985A (en) 2007-02-21
ZA200605239B (en) 2008-01-08
US20050113657A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
US7496392B2 (en) Fiber optic device for sensing analytes
US7787923B2 (en) Fiber optic device for sensing analytes and method of making same
US20050148003A1 (en) Methods of correcting a luminescence value, and methods of determining a corrected analyte concentration
EP1098658B1 (en) Engineered proteins for analyte sensing
US20030171666A1 (en) Internal biochemical sensing device
US20050267326A1 (en) Percutaneous chemical sensor based on fluorescence resonant energy transfer (FRET)
MXPA06005806A (en) Fiber optic device for sensing analytes
Lakowicz A glucose-sensing contact lens: from bench top to patient Ramachandram Badugu1, Joseph R Lakowicz1 and Chris D Geddes1, 2

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161114